Last Posted: May 20, 2017
- National Lipid Association Releases Updated Recommendations on the Use of PCSK9 Inhibitors at the 15th Annual Scientific Session
National Lipid Association, May 2017 - NLA Expert Panel on Treatment with PCSK9 Inhibitors: 2017 recommendations
National Lipid Association, May 2017 - PCSK9 Inhibition to Reduce Cardiovascular Risk: Tempering Expectations.
Waters David D et al. Circulation research 2017 May (10) 1537-1539 - PCSK9 monoclonal antibodies for the primary and secondary prevention of cardiovascular disease.
Schmidt Amand F et al. The Cochrane database of systematic reviews 2017 Apr CD011748 - Update on the use of PCSK9 inhibitors in adults: Recommendations from an Expert Panel of the National Lipid Association
CE Orringer et al, J Clin Lipidology, May 2017 - New data on familial hypercholesterolaemia and acute coronary syndromes: The promise of PCSK9 monoclonal antibodies in the light of recent clinical trials.
Ellis Katrina L et al. European journal of preventive cardiology 2017 Jan 2047487317708890 - Nine paths to PCSK9 inhibition
A Mullard, Nature Rev Drug Discovery, April 2017 - Genetic Architecture of Familial Hypercholesterolaemia.
Sharifi Mahtab et al. Current cardiology reports 2017 May 19(5) 44 - PCSK9 Inhibition to Reduce Cardiovascular Events.
Dullaart Robin P F et al. The New England journal of medicine 2017 Mar - PCSK9 Inhibition to Reduce Cardiovascular Events
Robin P.F. Dullaart, NEJM, March 17, 2017 - Analysis of Children and Adolescents with Familial Hypercholesterolemia.
Minicocci Ilenia et al. The Journal of pediatrics 2017 Feb - Eligibility for PCSK9 treatment in 734 Hypercholesterolemic patients referred to a regional cholesterol treatment center with LDL cholesterol ≥ 70 mg/dl despite maximal tolerated cholesterol lowering therapy.
Glueck Charles J et al. Lipids in health and disease 2016 Mar 1555 - Old challenges and new opportunities in the clinical management of heterozygous familial hypercholesterolemia (HeFH): The promises of PCSK9 inhibitors.
Arca Marcello et al. Atherosclerosis 2016 Sep - Variation in PCSK9 and HMGCR and Risk of Cardiovascular Disease and Diabetes
BA Ference et al, NEJM, November 30, 2016 - Cholesterol, Cardiovascular Risk, Statins, PCSK9 Inhibitors, and the Future of LDL-C Lowering.
Rodriguez Fatima et al. JAMA 2016 Nov 316(19) 1967-1968 - HEART UK statement on the management of homozygous familial hypercholesterolaemia in the United Kingdom.
France Michael et al. Atherosclerosis 2016 Nov
.png)
No hay comentarios:
Publicar un comentario